Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA:600521)
China · Delayed Price · Currency is CNY 16.21
+0.69 (4.45%)
Sep 16, 2026, 3:00 PM CST
SHA:600521 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 24,157 | 25,289 | 25,895 | 21,592 | 32,429 | 32,246 | |
Market Cap Growth | -32.91% | -2.34% | 19.93% | -33.42% | 0.57% | -34.43% |
Enterprise Value | 30,667 | 31,573 | 31,481 | 27,591 | 37,869 | 35,435 |
Last Close Price | 16.21 | 16.85 | 17.54 | 14.23 | 20.93 | 20.64 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 38.57 | 94.93 | 23.14 | 26.00 | 27.77 | 66.14 |
Forward PE | 20.65 | 13.58 | 17.02 | 15.44 | 24.43 | 20.78 |
PS Ratio | 2.69 | 2.95 | 2.71 | 2.60 | 3.92 | 4.85 |
PB Ratio | 2.40 | 2.67 | 2.87 | 2.62 | 4.19 | 4.76 |
P/TBV Ratio | 2.81 | 3.08 | 3.39 | 3.13 | 5.06 | 5.84 |
P/FCF Ratio | 600.02 | - | 81.09 | 34.57 | - | - |
P/OCF Ratio | 12.33 | 20.56 | 11.92 | 9.74 | 26.10 | 34.36 |
PEG Ratio | - | 1.49 | 1.49 | 1.49 | 1.49 | 1.49 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.41 | 3.68 | 3.30 | 3.32 | 4.58 | 5.33 |
EV/EBITDA Ratio | 16.95 | 19.91 | 12.42 | 12.89 | 16.98 | 33.74 |
EV/EBIT Ratio | 39.58 | 51.31 | 19.46 | 20.28 | 24.00 | 70.52 |
EV/FCF Ratio | 761.74 | - | 98.59 | 44.17 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.82 | 0.85 | 0.83 | 0.83 | 0.88 | 0.82 |
Debt / EBITDA Ratio | 4.54 | 4.98 | 2.95 | 3.20 | 3.01 | 5.18 |
Debt / FCF Ratio | 203.83 | - | 23.42 | 10.98 | - | - |
Net Debt / Equity Ratio | 0.62 | 0.68 | 0.65 | 0.66 | 0.68 | 0.54 |
Net Debt / EBITDA Ratio | 3.50 | 4.07 | 2.32 | 2.53 | 2.36 | 3.47 |
Net Debt / FCF Ratio | 155.10 | -8.77 | 18.42 | 8.68 | -4.91 | -2.44 |
Asset Turnover | 0.42 | 0.41 | 0.49 | 0.45 | 0.49 | 0.47 |
Inventory Turnover | 1.10 | 1.01 | 1.09 | 0.99 | 1.04 | 1.05 |
Quick Ratio | 0.60 | 0.53 | 0.82 | 0.74 | 0.91 | 0.90 |
Current Ratio | 1.05 | 0.96 | 1.42 | 1.40 | 1.65 | 1.61 |
Return on Equity (ROE) | 5.88% | 2.46% | 12.82% | 10.22% | 16.20% | 7.12% |
Return on Assets (ROA) | 2.24% | 1.84% | 5.21% | 4.63% | 5.87% | 2.21% |
Return on Invested Capital (ROIC) | 3.46% | 2.04% | 8.57% | 7.57% | 10.49% | 3.23% |
Return on Capital Employed (ROCE) | 5.80% | 5.00% | 11.30% | 10.30% | 11.80% | 4.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.60% | 1.05% | 4.32% | 3.85% | 3.60% | 1.51% |
FCF Yield | 0.17% | -2.91% | 1.23% | 2.89% | -3.31% | -4.64% |
Dividend Yield | 0.62% | 0.59% | 1.43% | 1.41% | 1.15% | 0.48% |
Payout Ratio | 111.03% | 205.02% | 42.48% | 66.95% | 27.26% | 79.42% |
Buyback Yield / Dilution | -1.23% | -1.84% | 0.26% | 0.19% | -1.80% | 1.30% |
Total Shareholder Return | -0.61% | -1.24% | 1.68% | 1.59% | -0.65% | 1.79% |